Literature DB >> 33693643

Estimated Half-Life of SARS-CoV-2 Anti-Spike Antibodies More Than Double the Half-Life of Anti-nucleocapsid Antibodies in Healthcare Workers.

Jan Van Elslande1, Lien Gruwier1, Lode Godderis2,3, Pieter Vermeersch1,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33693643      PMCID： PMC7989510          DOI： 10.1093/cid/ciab219

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  15 in total

1.  Longitudinal kinetics of RBD+ antibodies in COVID-19 recovered patients over 14 months.

Authors:  Tsuf Eyran; Anna Vaisman-Mentesh; David Taussig; Yael Dror; Ligal Aizik; Aya Kigel; Shai Rosenstein; Yael Bahar; Dor Ini; Ran Tur-Kaspa; Tatyana Kournos; Dana Marcoviciu; Dror Dicker; Yariv Wine
Journal:  PLoS Pathog       Date:  2022-06-03       Impact factor: 7.464

2.  Detection of silent infection of severe acute respiratory syndrome coronavirus 2 by serological tests.

Authors:  Masashi Nishimura; Satoshi Sugawa; Shinichiro Ota; Etsuko Suematsu; Masahiro Shinoda; Masaharu Shinkai
Journal:  PLoS One       Date:  2022-05-20       Impact factor: 3.752

3.  SARS-CoV-2-Induced Immunosuppression: A Molecular Mimicry Syndrome.

Authors:  Darja Kanduc
Journal:  Glob Med Genet       Date:  2022-07-14

4.  IgG Anti-Spike Antibodies and Surrogate Neutralizing Antibody Levels Decline Faster 3 to 10 Months After BNT162b2 Vaccination Than After SARS-CoV-2 Infection in Healthcare Workers.

Authors:  Bram Decru; Jan Van Elslande; Sophie Steels; Gijs Van Pottelbergh; Lode Godderis; Bram Van Holm; Xavier Bossuyt; Johan Van Weyenbergh; Piet Maes; Pieter Vermeersch
Journal:  Front Immunol       Date:  2022-06-15       Impact factor: 8.786

Review 5.  Persistence and viability of SARS-CoV-2 in primary infection and reinfections.

Authors:  J Ruiz-Galiana; P De Lucas Ramos; A García-Botella; A García-Lledó; J Gómez-Pavón; J González Del Castillo; T Hernández-Sampelayo; M C Martín-Delgado; F J Martín Sánchez; M Martínez-Sellés; J M Molero García; S Moreno Guillén; F J Rodríguez-Artalejo; R Cantón; E Bouza
Journal:  Rev Esp Quimioter       Date:  2021-10-18       Impact factor: 1.553

6.  Robust and Functional Immune Memory Up to 9 Months After SARS-CoV-2 Infection: A Southeast Asian Longitudinal Cohort.

Authors:  Hoa Thi My Vo; Alvino Maestri; Heidi Auerswald; Sopheak Sorn; Sokchea Lay; Heng Seng; Sotheary Sann; Nisa Ya; Polidy Pean; Philippe Dussart; Olivier Schwartz; Sovann Ly; Timothée Bruel; Sowath Ly; Veasna Duong; Erik A Karlsson; Tineke Cantaert
Journal:  Front Immunol       Date:  2022-02-03       Impact factor: 7.561

7.  Long-term SARS-CoV-2-specific and cross-reactive cellular immune responses correlate with humoral responses, disease severity, and symptomatology.

Authors:  Ida Laurén; Sebastian Havervall; Henry Ng; Martin Lord; Aleksandra Pettke; Nina Greilert-Norin; Lena Gabrielsson; Aikaterini Chourlia; Catarina Amoêdo-Leite; Vijay S Josyula; Mohamed Eltahir; Iliana Kerzeli; August J Falk; Jonathan Hober; Wanda Christ; Anna Wiberg; My Hedhammar; Hanna Tegel; Joachim Burman; Feifei Xu; Elisa Pin; Anna Månberg; Jonas Klingström; Gustaf Christoffersson; Sophia Hober; Peter Nilsson; Mia Philipson; Pierre Dönnes; Robin Lindsay; Charlotte Thålin; Sara Mangsbo
Journal:  Immun Inflamm Dis       Date:  2022-04

8.  SARS-COV-2 seroprevalence among employees of a University Hospital in Belgium during the 2020 COVID-19 outbreak (COVEMUZ-study).

Authors:  Deborah De Geyter; Ellen Vancutsem; Sven Van Laere; Denis Piérard; Patrick Lacor; Ilse Weets; Sabine Allard
Journal:  Epidemiol Infect       Date:  2021-07-05       Impact factor: 2.451

9.  IgG anti-spike antibody levels in healthcare workers with and without prior COVID-19 up to 3 months after BNT162b2 vaccination.

Authors:  Jan Van Elslande; Matthias Weemaes; Lode Godderis; Gijs Van Pottelbergh; Xavier Bossuyt; Pieter Vermeersch
Journal:  Diagn Microbiol Infect Dis       Date:  2022-01-16       Impact factor: 2.983

10.  Lower persistence of anti-nucleocapsid compared to anti-spike antibodies up to one year after SARS-CoV-2 infection.

Authors:  Jan Van Elslande; Matthijs Oyaert; Natalie Lorent; Yannick Vande Weygaerde; Gijs Van Pottelbergh; Lode Godderis; Marc Van Ranst; Emmanuel André; Elizaveta Padalko; Katrien Lagrou; Stien Vandendriessche; Pieter Vermeersch
Journal:  Diagn Microbiol Infect Dis       Date:  2022-02-12       Impact factor: 2.803
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.